BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $590,000 | -79.8% | 3,899 | -80.5% | 0.00% | -66.7% |
| Q2 2022 | $2,914,000 | -41.8% | 20,004 | -72.7% | 0.00% | -25.0% |
| Q1 2021 | $5,006,000 | -69.7% | 73,232 | -62.0% | 0.00% | -69.2% |
| Q4 2020 | $16,504,000 | -54.9% | 192,562 | -65.8% | 0.01% | -51.9% |
| Q3 2020 | $36,603,000 | +10.1% | 563,040 | +23.9% | 0.03% | -30.8% |
| Q2 2020 | $33,231,000 | +781.2% | 454,509 | +310.2% | 0.04% | +680.0% |
| Q1 2020 | $3,771,000 | +305.9% | 110,812 | +422.5% | 0.01% | +400.0% |
| Q2 2019 | $929,000 | -87.3% | 21,209 | -85.1% | 0.00% | -87.5% |
| Q1 2019 | $7,327,000 | +841.8% | 142,349 | +577.2% | 0.01% | +700.0% |
| Q4 2018 | $778,000 | -35.3% | 21,019 | -54.9% | 0.00% | 0.0% |
| Q1 2018 | $1,202,000 | +2695.3% | 46,653 | +2823.1% | 0.00% | – |
| Q4 2017 | $43,000 | – | 1,596 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |